SecBot SecBot
SECBOTREPLAY Home › Report › LAB

LAB · Standard BioTools terminated its prior agreement to sell its mass…

STANDARD BIOTOOLS INC. · 425 filed Sep 30, 2026 at 17:28 ET

At the news

BULLISHIMPACT 6/10

425 filed Sep 30, 2026 at 17:28 ET

Standard BioTools terminated its prior agreement to sell its mass cytometry business to Multiplex Bio and entered into a new $5.5 million cash deal with Element Biosystems (GMT Venture), which the board deemed a superior proposal. The new deal eliminates a $10 million working capital loan obligation, improving net cash by ~$15 million for the pending Treeline merger. The transaction requires stockholder approval and is expected to close by end of 2026 concurrently with the Treeline merger.

  • Standard BioTools terminated the Multiplex Bio purchase agreement and entered a new agreement with Element Biosystems (GMT Venture) for $5.5 million cash.
  • The new deal eliminates a $10 million working capital loan that was required under the Multiplex Bio agreement.
  • Net cash position for the Treeline merger exchange ratio calculation improves by approximately $15 million versus the Multiplex Bio deal.
  • GMT Venture paid $1.0 million of the $1.5 million Multiplex Bio termination fee on Standard BioTools' behalf.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access